Oncotarget

Research Papers:

A potential prognostic lncRNA signature for predicting survival in patients with bladder urothelial carcinoma

Zhenyu Bao, Weitao Zhang and Dong Dong _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:10485-10497. https://doi.org/10.18632/oncotarget.14441

Metrics: PDF 2511 views  |   HTML 2634 views  |   ?  


Abstract

Zhenyu Bao1,*, Weitao Zhang2,*, Dong Dong1

1Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University, Shanghai, China

2Urology Surgery Department, Affiliated Hospital of Taishan Medical University, Shandong, China

*These authors have contributed equally to this work

Correspondence to:

Dong Dong, email: [email protected]

Keywords: long non-coding RNA, prognosis, bladder urothelial carcinoma

Received: October 15, 2016    Accepted: December 08, 2016    Published: January 02, 2017

ABSTRACT

Increasing evidence has highlighted the critical roles of long non-coding RNA (lncRNA) in cancer development and progression. However, the prognostic power of expression-based lncRNA signature for predicting overall survival in patients with Bladder Urothelial Carcinoma (BLCA) has not been investigated. Here, we performed a comprehensive analysis for lncRNA expression profiles and corresponding clinical information of 234 BLCA patients from The Cancer Genome Atlas (TCGA). We established a set of four-lncRNAs that were significantly associated with BLCA patients’ survival. Using the prognostic four-lncRNA signature, we successfully classified the BLCA patients into high-risk and low-risk groups, and the prognostic power of the four-lncRNA signature was further validated in the testing dataset and entire dataset. Multivariate Cox regression and stratified analyses demonstrated that the prognostic power of the four-lncRNA signature was independent of other clinical variables. Functional enrichment analyses suggested the four prognostic lncRNAs may be involved in known BLCA-related biological processes and pathways. Our results demonstrated that the four-lncRNA signature could be novel independent biomarkers for predicting survival in patients with BLCA.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14441